Sigachi Industries Ltd

Sigachi Industries, a small-cap firm in the Pharmaceuticals & Drugs sector, has hit a new 52-week low amid significant volatility. The stock has dropped consecutively over two days, reflecting a challenging year with a notable decline, contrasting sharply with broader market performance.

Sigachi Industries, a small-cap firm in the Pharmaceuticals & Drugs sector, has hit a new 52-week low, reflecting significant volatility and a 19.17% decline over the past nine days. The stock has decreased by 47.95% over the past year, underperforming against the broader market.

Sigachi Industries has faced significant volatility, reaching a new 52-week low and experiencing an eight-day decline, resulting in a cumulative drop of nearly 15%. The company's stock has underperformed its sector and is trading below key moving averages, reflecting ongoing challenges in a competitive market.

Sigachi Industries, a small-cap firm in the Pharmaceuticals & Drugs sector, has hit a new 52-week low, continuing a downward trend with an 11.66% decline over the past week. The stock has dropped 47.85% in the past year, underperforming against the Sensex, which has gained 8.21%.

Sigachi Industries, a small-cap company in the Pharmaceuticals & Drugs sector, has hit a new 52-week low, marking a significant downturn. The stock has declined 46.77% over the past year, underperforming the Sensex, and is trading below multiple moving averages, indicating ongoing challenges in the market.

Sigachi Industries has faced significant volatility, hitting a new 52-week low and underperforming its sector. The stock has declined 44.40% over the past year, contrasting with the Sensex's positive performance. Currently, it trades below multiple moving averages, indicating ongoing challenges in the market.

Sigachi Industries, a small-cap firm in the Pharmaceuticals & Drugs sector, has hit a new 52-week low amid significant volatility. The stock has seen consecutive losses over four days and a substantial decline over the past year, underperforming compared to broader market indices.

Sigachi Industries has reported its third-quarter financial results for FY24-25, highlighting significant growth in key metrics. Profit Before Tax reached Rs 24.69 crore, while net sales hit a record Rs 139.42 crore. However, the company faces challenges with rising interest costs and declining turnover ratios.

Sigachi Industries, a smallcap pharmaceutical company, saw a significant increase in its stock price on November 29, 2024. Despite a 'Sell' call from MarketsMOJO, the company's performance has been impressive with a consecutive gain for the last 3 days and a rise of 16.08% in returns. The stock also outperformed the sector and the overall market, indicating potential for growth in the future.

On November 27, 2024, Sigachi Industries, a smallcap pharmaceutical company, saw a 7.47% increase in its stock price, outperforming the sector by 7.97%. Despite this, MarketsMOJO has given a 'Sell' call for the stock. It is currently trading higher than its short-term moving averages but lower than its long-term ones, indicating a mixed trend. It has also outperformed the overall market in the past 1 day and 1 month. However, this is not a recommendation and investors should conduct their own research before making any decisions.

Sigachi Industries, a smallcap pharmaceutical company, has reported its financial results for the second quarter of fiscal year 2024-25. While there has been a slight improvement in the overall score, the company's profit after tax and net sales have shown significant growth. However, profit before tax has declined and there are concerns about the company's non-operating income and debt-equity ratio.

On September 20, 2024, Sigachi Industries' stock price increased by 7.02%, in line with the pharmaceutical and drugs industry. According to MarketsMOJO, the current stock call for Sigachi Industries is 'Sell', based on recent performance and market trends. The stock has shown a mixed trend in the short term and has outperformed the Sensex in the past day, but underperformed in the past month. Investors should carefully consider these factors before making any decisions.

Sigachi Industries, a smallcap pharmaceutical company, has been downgraded to a 'Sell' by MarketsMOJO due to its flat results, high debt and interest expenses. Despite outperforming the market, the stock is currently in a bearish range and has an expensive valuation. Domestic mutual funds hold 0% of the company, indicating potential concerns.

Sigachi Industries, a smallcap pharmaceutical company, reported a flat performance in the quarter ending March 2024 with a score of 0 compared to -2 in the previous quarter. However, net sales for the half-yearly period have grown by 27.19% year on year and operating profit margin is at its highest in the last five quarters. On the downside, the debtors turnover ratio and interest cost have raised concerns, while profit after tax has fallen by -7.9% and debt-equity ratio is at its highest in the last five periods. Investors are advised to hold their positions and closely monitor the company's performance.

Sigachi Industries, a smallcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its low Debt to Equity ratio of 0.02 times. The stock has been in a Mildly Bullish range since 25-Jul-24 and has outperformed the market with a return of 115.17% in the last year. However, its financials and valuation should be carefully evaluated before making any investment decisions.

Sigachi Industries, a smallcap pharmaceutical company, saw a 8.05% increase in its stock price on July 25th, 2024. Despite a 'Sell' call from MarketsMOJO, the company has outperformed its sector by 6.8% and has been on a consecutive gain for the last 3 days. Moving averages show a mixed trend for the stock.

Sigachi Industries, a smallcap pharmaceutical company, has been downgraded to 'Sell' by MarketsMOJO due to its flat results in March 2024 and low DEBTORS TURNOVER RATIO(HY) and OPERATING PROFIT TO INTEREST (Q). The stock is trading at a discount and has a high PEG ratio. Domestic mutual funds hold 0% of the company, indicating potential concerns.

Sigachi Industries, a smallcap pharmaceutical company, received a 'Hold' rating from MarketsMOJO on May 30, 2024. The company has a low Debt to Equity ratio of 0.02 times, indicating a stable financial position. However, the stock has shown a -3.41% return since the upgrade and has outperformed the market with a return of 169.38% in the last year. In the latest quarter, Sigachi Industries reported flat results with a decrease of -29.9% in PBT LESS OI(Q). The company's DEBTORS TURNOVER RATIO(HY) and OPERATING PROFIT TO INTEREST (Q) are at their lowest. Despite a high ROCE and expensive valuation, the stock is currently trading at a discount compared to its historical valuations. Domestic mutual funds hold 0% of Sigachi Industries, possibly due to discomfort with the current price or lack of research on the company.